Standard Contracts
AGREEMENTParticipation Agreement • May 15th, 2001 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah
Contract Type FiledMay 15th, 2001 Company Industry Jurisdiction
EXHIBIT 1.1 3,000,000 Shares Myriad Genetics, Inc. COMMON STOCK, $0.01 par value UNDERWRITING AGREEMENT November 21, 2002 Morgan Stanley & Co. Incorporated 1585 Broadway New York, New York 10036 Dear Sirs and Mesdames: Myriad Genetics, Inc., a...Underwriting Agreement • November 26th, 2002 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledNovember 26th, 2002 Company Industry Jurisdiction
EXHIBIT 10.1Lease Agreement • May 15th, 2001 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah
Contract Type FiledMay 15th, 2001 Company Industry Jurisdiction
d) "Affiliate" and "Associate" shall have the respective --------- --------- meanings ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended and in effect on the date of this...Rights Agreement • July 18th, 2001 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledJuly 18th, 2001 Company Industry Jurisdiction
EXHIBIT 1.1 2,000,000 Shares MYRIAD GENETICS, INC. Common Stock $0.01 par value UNDERWRITING AGREEMENTUnderwriting Agreement • March 14th, 2000 • Myriad Genetics Inc • Services-commercial physical & biological research • New York
Contract Type FiledMarch 14th, 2000 Company Industry Jurisdiction
129,665 SHARES OF COMMON STOCK STOCK PURCHASE AGREEMENT DATED AS OF APRIL 22, 1997 MYRIAD GENETICS, INC. STOCK PURCHASE AGREEMENT THIS AGREEMENT, made as of April 22, 1997, is by and between MYRIAD GENETICS, INC. (the "Company"), a Delaware...Stock Purchase Agreement • September 29th, 1997 • Myriad Genetics Inc • Services-commercial physical & biological research
Contract Type FiledSeptember 29th, 1997 Company Industry
This PURCHASE AGREEMENT (this "Agreement"), dated as of October 27, 2000, --------- is entered into by and between Myriad Genetics Inc., a Delaware corporation with offices at 320 Wakara Way, Salt Lake City, Utah 84108 (the "Company"), and Acqua...Purchase Agreement • November 22nd, 2000 • Myriad Genetics Inc • Services-commercial physical & biological research
Contract Type FiledNovember 22nd, 2000 Company Industry
EXHIBIT 10.3 SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 15th, 1999 • Myriad Genetics Inc • Services-commercial physical & biological research • Delaware
Contract Type FiledNovember 15th, 1999 Company Industry Jurisdiction
Exhibit 10.44 LEASE AGREEMENT LANDLORD: BOYER RESEARCH PARK ASSOCIATES VI, BY ITS GENERAL PARTNER, THE BOYER COMPANY, L.C. TENANT: MYRIAD GENETICS, INC. TABLE OF CONTENTS -----------------Lease Agreement • September 24th, 1998 • Myriad Genetics Inc • Services-commercial physical & biological research • Utah
Contract Type FiledSeptember 24th, 1998 Company Industry Jurisdiction
Exhibit 4.5 REGISTRATION RIGHTS AGREEMENT ----------------------------- This Registration Rights Agreement is made and entered into as of October 27, 2000 (this "Agreement"), by and between Myriad Genetics Inc., a Delaware corporation (the "Company"),...Registration Rights Agreement • November 22nd, 2000 • Myriad Genetics Inc • Services-commercial physical & biological research • New York
Contract Type FiledNovember 22nd, 2000 Company Industry Jurisdiction
SCHEDULE to the Master Agreement dated as of October 8, 1997 betweenMaster Agreement • November 14th, 1997 • Myriad Genetics Inc • Services-commercial physical & biological research • New York
Contract Type FiledNovember 14th, 1997 Company Industry Jurisdiction
RECITALS --------Subordination Agreement • November 12th, 1998 • Myriad Genetics Inc • Services-commercial physical & biological research
Contract Type FiledNovember 12th, 1998 Company Industry
CREDIT AGREEMENT dated as of June 30, 2023 among MYRIAD GENETICS, INC. The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent ___________________________ JPMORGAN CHASE BANK, N.A. and WELLS FARGO BANK, NATIONAL ASSOCIATION, as...Credit Agreement • July 6th, 2023 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledJuly 6th, 2023 Company Industry JurisdictionCREDIT AGREEMENT dated as of June 30, 2023 (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”), among MYRIAD GENETICS, INC., as Borrower, the other Loan Parties party hereto, the Lenders party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent and Issuing Bank.
Exhibit 10.3 AMENDMENT NO. 1 TO MASTER LEASE AGREEMENT DATED OCTOBER 25, 1999 (the "Lease") BY AND BETWEEN MYRIAD GENETICS, INC. ("Lessee") AND COMDISCO LABORATORY AND SCIENTIFIC GROUP, A DIVISION OF COMDISCO HEALTHCARE GROUP, INC. ("Lessor") WHEREAS,...Master Lease Agreement • February 14th, 2000 • Myriad Genetics Inc • Services-commercial physical & biological research
Contract Type FiledFebruary 14th, 2000 Company Industry
Myriad Genetics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • November 13th, 2023 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances
Contract Type FiledNovember 13th, 2023 Company IndustryMyriad Genetics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 6,470,588 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 970,588 additional shares (the “Optional Securities”) of common stock, par value $0.01 per share (“Stock”) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
WITNESSETH:Standstill Agreement • September 29th, 1997 • Myriad Genetics Inc • Services-commercial physical & biological research • Delaware
Contract Type FiledSeptember 29th, 1997 Company Industry Jurisdiction
MYRIAD GENETICS, INC. INDENTURE Dated as of DEBT SECURITIES TrusteeIndenture • November 8th, 2023 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledNovember 8th, 2023 Company Industry JurisdictionWHEREAS, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of unsecured debentures, notes, bonds or other evidences of indebtedness (the “Securities”) in an unlimited aggregate principal amount to be issued from time to time in one or more series as provided in this Indenture; and
CREDIT AGREEMENT dated as of August 31, 2016 among MYRIAD GENETICS, INC. The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A. as Administrative Agent JPMORGAN CHASE BANK, N.A., as Sole Bookrunner and Sole Lead ArrangerCredit Agreement • November 2nd, 2016 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledNovember 2nd, 2016 Company Industry JurisdictionCREDIT AGREEMENT (this “Agreement”) dated as of August 31, 2016 among MYRIAD GENETICS, INC., a Delaware corporation, the LENDERS from time to time party hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent.
Exhibit 10.2 SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT is made as of the 30th day of September, 1999, by and between Myriad Genetics, Inc. (the "Company"), a Delaware corporation with primary offices at 320 Wakara Way, Salt Lake City, Utah...Subscription Agreement • November 15th, 1999 • Myriad Genetics Inc • Services-commercial physical & biological research • Delaware
Contract Type FiledNovember 15th, 1999 Company Industry Jurisdiction
RECITALS --------Collaboration and License Agreement • November 15th, 1999 • Myriad Genetics Inc • Services-commercial physical & biological research • Utah
Contract Type FiledNovember 15th, 1999 Company Industry Jurisdiction
R E C I T A L S:Lease Agreement • November 8th, 1996 • Myriad Genetics Inc • Services-commercial physical & biological research
Contract Type FiledNovember 8th, 1996 Company Industry
Exhibit 10.9 COLLABORATIVE PRONET RESEARCH AND LICENSE AGREEMENT dated as of November 11, 1998Collaborative Research and License Agreement • February 12th, 1999 • Myriad Genetics Inc • Services-commercial physical & biological research • Delaware
Contract Type FiledFebruary 12th, 1999 Company Industry Jurisdiction
EXHIBIT 10.36 RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • September 29th, 1997 • Myriad Genetics Inc • Services-commercial physical & biological research • New York
Contract Type FiledSeptember 29th, 1997 Company Industry Jurisdiction
EXHIBIT 10.1 ------------ MYRIAD GENETICS, INC. HAS OMITTED FROM THIS EXHIBIT 10.1 PORTIONS OF THE AGREEMENT FOR WHICH MYRIAD GENETICS, INC. HAS REQUESTED CONFIDENTIAL TREATMENT FROM THE SECURITIES AND EXCHANGE COMMISSION. THE PORTIONS OF THE...Patent and Technology License Agreement • April 24th, 1997 • Myriad Genetics Inc • Services-commercial physical & biological research • Texas
Contract Type FiledApril 24th, 1997 Company Industry Jurisdiction
Myriad Genetics, Inc. 7,000,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • November 4th, 2005 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledNovember 4th, 2005 Company Industry JurisdictionMyriad Genetics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 7,000,000 shares of Common Stock, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,050,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are herein referred to as the “Stock.” The Stock, including the Shares, will have attached thereto rights (the “Rights”) to purchase from the Company, upon the occurrence of certain events, a unit consisting of one one-hundredth of a share of the Company’s Series A Junior Participating Preferred Stock, $0.01 par value per
MYRIAD GENETICS, INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • November 1st, 2007 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware
Contract Type FiledNovember 1st, 2007 Company Industry JurisdictionThis Agreement sets forth the terms of the incentive stock option (“ISO”) grant made by Myriad Genetics, Inc. (the “Company”), a Delaware corporation having a principal place of business in Salt Lake City, Utah, to the individual specified in the Notice of Grant of Stock Option and Option Agreement (the “Employee”).
NEXUS ON GRAND LEASELease • February 28th, 2024 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • California
Contract Type FiledFebruary 28th, 2024 Company Industry JurisdictionThis Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between BAYSIDE AREA DEVELOPMENT, LLC, a Delaware limited liability company ("Landlord"), and MYRIAD GENETICS, INC., a Delaware corporation ("Tenant").
PLEDGE AND SECURITY AGREEMENTPledge and Security Agreement • July 6th, 2023 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledJuly 6th, 2023 Company Industry JurisdictionTHIS PLEDGE AND SECURITY AGREEMENT (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”) is entered into as of June 30, 2023 by and among MYRIAD GENETICS, INC., a Delaware corporation (the “Borrower”), MYRIAD GENETICS LABORATORIES, INC., a Delaware corporation, MYRIAD WOMEN’S HEALTH, INC., a Delaware corporation, ASSUREX HEALTH, INC., a Delaware corporation, GATEWAY GENOMICS, LLC, a Delaware limited liability company, any additional entities which become parties to this Security Agreement by executing a Security Agreement Supplement hereto in substantially the form of Annex I hereto (such additional entities, together with the Borrower, Myriad Genetics Laboratories, Inc., Myriad Women’s Health, Inc., Assurex Health, Inc. and Gateway Genomics, LLC, each a “Grantor”, and collectively, the “Grantors”), and JPMorgan Chase Bank, N.A., in its capacity as administrative agent (the “Administrative Agent”) for the
RECITALSLicense Agreement • May 15th, 2001 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware
Contract Type FiledMay 15th, 2001 Company Industry Jurisdiction
INDEMNIFICATION AGREEMENTIndemnification Agreement • November 7th, 2018 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware
Contract Type FiledNovember 7th, 2018 Company Industry JurisdictionTHIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this ___ day of __________, by and between MYRIAD GENETICS, INC., a Delaware corporation (the “Corporation”), and ___________________________________________________ (“Agent”).
AGREEMENT ---------Immunity Agreement • November 14th, 1996 • Myriad Genetics Inc • Services-commercial physical & biological research • New Jersey
Contract Type FiledNovember 14th, 1996 Company Industry Jurisdiction
Executive Retention AgreementExecutive Retention Agreement • February 7th, 2020 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah
Contract Type FiledFebruary 7th, 2020 Company Industry JurisdictionTHIS EXECUTIVE RETENTION AGREEMENT (this “Agreement”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and ________________________ (the “Executive”), is made as of ________________________, (the “Effective Date”).
Exhibit 10.1 MASTER LEASE AGREEMENT dated as of December 31, 1998 ("AGREEMENT") THIS AGREEMENT, is between GENERAL ELECTRIC CAPITAL CORPORATION its successors and assigns, if any ("LESSOR") and MYRIAD GENETICS, INC. ("LESSEE"). Lessor has an office at...Master Lease Agreement • February 12th, 1999 • Myriad Genetics Inc • Services-commercial physical & biological research
Contract Type FiledFebruary 12th, 1999 Company Industry
3,400,000 Shares Myriad Genetics, Inc. COMMON STOCK, $0.01 par value UNDERWRITING AGREEMENTUnderwriting Agreement • June 4th, 2004 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledJune 4th, 2004 Company Industry JurisdictionMyriad Genetics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Morgan Stanley & Co. Incorporated (the “Underwriter”) 3,400,000 shares of its common stock, $0.01 par value per share (the “Firm Shares”). The Company also proposes to issue and sell to the Underwriter not more than an additional 510,000 shares of its common stock, $0.01 par value per share (the “Additional Shares”), if and to the extent that you shall have determined to exercise the right to purchase such shares of common stock granted to you in Section 2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the “Shares.” The shares of common stock, $0.01 par value per share, of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the “Common Stock.”
SUBLEASE AGREEMENTSublease Agreement • July 7th, 2009 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah
Contract Type FiledJuly 7th, 2009 Company Industry Jurisdictionchange order. The cost of any change orders that are necessary to comply with applicable building codes and other laws shall be borne by Landlord, unless such change orders are necessitated only because of (1) other change orders requested by Tenant; (2) Tenant Finish Plans; (3) changes to Tenant Finish Plans; or (4) Tenant’s early occupancy to the Building prior to substantial completion of Landlord’s Work. Any change order shall be effective only when set forth on a written change order executed by Landlord, Tenant, and the Base Building General Contractor. By approving a change order, Tenant and Landlord shall agree to a delay in Substantial Completion and to the Target Date, as specified therein, if any.